Trials / Recruiting
RecruitingNCT05819866
A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects With Cerebral Adrenoleukodystrophy
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Minoryx Therapeutics, S.L. · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adults Male Subjects with Cerebral Adrenoleukodystrophy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Leriglitazone | Leriglitazone at a strength of 15 mg/ml. Once-daily dosing at an initial volume of 10 ml |
| DRUG | Placebo | Placebo will match the study drug visually and by taste |
Timeline
- Start date
- 2023-07-12
- Primary completion
- 2027-05-01
- Completion
- 2027-05-01
- First posted
- 2023-04-19
- Last updated
- 2025-11-17
Locations
13 sites across 8 countries: United States, Argentina, Brazil, France, Germany, India, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05819866. Inclusion in this directory is not an endorsement.